Novartis Keeps Grip On Eye Drug Patent In Fed. Circ.
Though the appeals court said that most of Novartis-unit Alcon Inc.'s patent was invalid because it had been predicted by a 1995 scientific study, it said the study didn't describe two of patent's eight infringed claims, meaning they were valid.
The decision means that U.S. District Judge Richard L. Young's...
To view the full article, register now.